Abstract
Paraneoplastic neurological syndromes (PNS) are a group of rare and severe immune-mediated disorders that affect the nervous system in patients with cancer. The best way to diagnose a paraneoplastic neurological disorder is to identify anti-onconeural protein antibodies that are specifically associated with various cancers. The aim of this multicentric study was to clinically and immunologically characterize patients with PNS and study their association with cancer. Patients suspected to have PNS were enrolled from various clinical centres and were characterized immunologically. This study population consisted of 112 patients. Onset of PNS was mainly subacute (76%). PNS patients had various neurological disorders and symptoms. PNS developed before the diagnosis of cancer in 28 definite PNS patients and in six suspected PNS patients. The most frequent autoantibodies detected in PNS patients were anti-Hu and anti-Yo. One definite PNS patient with cerebellar syndrome had anti-Tr antibody and seven patients had atypical antibodies. The literature associates these antibodies with various neurological disorders and cancers. Our observations confirm the important role of autoantibodies in PNS and their importance for the early diagnosis of cancer in PNS patients.
Similar content being viewed by others
References
Antoine JC and Camdessanchè JP 2007 Peripheral nervous system involvement in patients with cancer. Lancet Neurol. 6 75–86
Antoine JC and Camdessanché JP 2013 Treatment options in paraneoplastic disorders of the peripheral nervous system. Curr. Treat. Options Neurol. 15 210–223
Armangué T, Sabater L, Torres-Vega E, Martínez-Hernández E, Ariño H, Petit-Pedrol M, Planagumà J, Bataller L, Dalmau J and Graus F 2016 Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol. 73 417–424
Asztely F and Kumlien E 2012 The diagnosis and treatment of limbic encephalitis. Acta Neurol. Scand. 126 365–375
Berger B, Bischler P, Dersch R, Hottenrott T, Rauer S and Stich O 2015 “Non-classical” paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to “classical” syndromes—More frequent than expected. J. Neurol. Sci. 352 58–61
Bernal F, Shams’ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, Honnorat J, Sillevis Smitt P and Graus F 2003 Anti-Tr antibodies as markers of paraneoplasticcerebellar degeneration and Hodgkin’s disease. Neurology 60 230–234
Blaes F 2012 Paraneoplastic neurological syndromes-diagnosis and management. Curr. Pharm. Des. 18 4518–4525
Blyakhman I and Chakravarthy K 2019 Updated review and treatment recommendations on paraneoplastic neurologic syndromes and chronic pain. Pain Physician 22 433–445
Chan AM and Baehring JM 2019 Paraneoplastic neurological syndromes: a single institution 10-year case series. J. Neurooncol. 141 431–439
Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, Saiz A, Meneses P and Rosenfeld MR 2004 Clinical analysis of anti-Ma2-associated encephalitis. Brain 127 1831–1844
Dalmau J and Rosenfeld MR 2008 Paraneoplastic syndromes of the CNS. Lancet Neurol. 7 327–340
Darnell RB and Posner JB 2003 Paraneoplastic syndromes involving the nervous system. N. Engl. J. Med. 349 1543–1554
Dankó K, Ponyi A, Molnar AP, András C and Constantin T 2009 Paraneoplastic myopathy. Curr. Opin. Rheumatol. 21 594–598
Daroff RB, Jankovic J, Mazziotta JC and Pomeroy SL 2016 Bradley’s neurology in clinical practice, 7th edition, (London, Elsevier)
Dean S, McCracken J, Kosmider S and Herath D 2018 Lambert-Eaton myasthenic syndrome developing post-diagnosis of small-cell lung cancer. Intern. Med. J. 48 1541–1542
England JD and Asbury AK 2004 Peripheral neuropathy. Lancet 363 2151–2161
Gordon L and Dinkin M 2019 Paraneoplastic syndromes in neuro-ophthalmology. Continuum (Minneap. Minn.) 25 1401–1421
Graus F and Dalmau J 2019 Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 16 535–548
Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J,Smitt PS, Vedeler Ch, Verschuuren JJ, Vincent A and Voltz R 2004 Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry 75 1135–1140
Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, Escaramis, G and Delattre JY 2001 Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain 124 1138–1144
Gutmann L, Crosby TW, Takamori M and Martin JD 1972 The Eaton-Lambert syndrome and autoimmune disorders. Am. J. Med. 53 354–356
Honnorat J and Antoine JC 2007 Paraneoplastic neurological syndromes. Orphanet J. Rare Dis. 2 22
Kanikannan MA, Sirisha Y, Uppin MS, Jabeen SA, Kandadai RM, Sundaram C, Raghunadharao D and Borgohain R 2015 Incidence and spectrum of paraneoplastic neurological syndromes: Single center study. J. Neurooncol. 125 197–206
Kazarian M and Laird-Offringa IA 2011 Small-cell lung cancer-associated autoantibodies: Potential applications to cancer diagnosis, early detection, and therapy. Mol. Cancer. 10 33
Lancaster E 2017 Paraneoplastic disorders. Continuum (Minneap. Minn.) 6 1653–1679
Longo V, Brunetti O, Azzariti A, Galetta D, Nardulli P, Leonetti F and Silvestris N 2019 Strategies to improve cancer immune checkpoint inhibitors efficacy, other than abscopal effect: A systematic review. Cancers 11 539
Lukacs S, Szabo N and Woodhams S 2012 Rare association of anti-hu antibody positive paraneoplastic neurological syndrome and transitional cell bladder carcinoma. Case Rep. Urol. 2012 724940
McKeon A, Tracy JA, Pittock SJ, Parisi JE, Klein CJ and Lennon VA 2011 Purkinje cell cytoplasmic autoantibody type 1 accompaniments: The cerebellum and beyond. Arch. Neurol. 68 1282–1289
Mélé N, Berzero G, Maisonobe T, Salachas F, Nicolas G, Weiss N, Beaudonnet G, Ducray F, Psimaras D and Lenglet T 2018 Motor neuron disease of paraneoplastic origin: a rare but treatable condition. J. Neurol. 265 1590–1599
Murinson BB and Guarnaccia JB 2008 Stiff-person syndrome with amphiphysin antibodies: Distinctive features of a rare disease. Neurology 71 1955–1958
Ortega Suero G, Sola-Valls N, Escudero D, Saiz A and Graus F 2018 Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes. Neurology 33 18–27
Rosenfeld MR and Dalmau J 2018 Paraneoplastic neurologic syndromes. Neurol. Clin. 36 675–685
Sæther SG, Schou M and Kondziella D 2017 What is the significance of onconeural antibodies for psychiatric symptomatology? A systematic review. BMC Psychiatry 17 161
Van Coevorden-Hameete MH, Titulaer MJ, Schreurs MW, de Graaff E, Sillevis Smitt PA and Hoogenraad CC 2016 Detection and characterization of autoantibodies to neuronal cell-surface antigens in the central nervous system. Front. Mol. Neurosci. 9 37
Venkatraman A and Opal P 2016 Paraneoplastic cerebellar degeneration with anti-Yo antibodies – A review. Ann. Clin. Transl. Neurol. 3 655–663
Vincent A 2005 Antibodies associated with paraneoplastic neurological disorders. Neurol. Sci. 26 s3–s4
Zaborowski MP and Michalak S 2013 Cell-mediated immune responses in paraneoplastic neurological syndromes. Clin. Dev. Immunol. 2013 630602
Zidan A, Fein A and Zuchowski K 2019 The use, misuse and abuse of paraneoplastic panels in neurological disorders. A retrospective study. Clin. Neurol. Neurosurg. 186 105545
Zis P, Paladini A, Piroli A, McHugh PC, Varrassi G and Hadjivassiliou M 2017 Pain as a first manifestation of paraneoplastic neuropathies: A systematic review and meta-analysis. Pain Ther. 6 143–151
Zoccarato M, Gastaldi M, Zuliani L, Biagioli T, Brogi M, et al. 2017 Diagnostics of paraneoplastic neurological syndromes. Neurol. Sci. 38 237–242
Acknowledgements
We would like to thank Marco L. Rossi for his support and encouragement in this study.
Funding
PNS-Euronetwork supported by the European Commission (QLGT-CT-2002-01756; LSSM-CT-2005 518174).
Author information
Authors and Affiliations
Corresponding author
Additional information
This paper is dedicated to the memory of the late Prof. Ian Kirkland Hart (1958–2008).
Corresponding editor: Aurnab Ghose
Rights and permissions
About this article
Cite this article
Lorusso, L., Precone, V., Hart, I.K. et al. Immunophenotypical characterization of paraneoplastic neurological syndrome patients: a multicentric study. J Biosci 46, 13 (2021). https://doi.org/10.1007/s12038-020-00128-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12038-020-00128-0